Uncovering dormancy in colorectal cancer 🧬
Colorectal cancer remains one of the most prevalent and deadly cancers worldwide, with up to 50% of patients relapsing after treatment.
This study explores tumour dormancy and biomarkers to predict recurrence.
pubmed.ncbi.nlm.nih....
18.11.2025 12:00 — 👍 0 🔁 0 💬 0 📌 0
ALADDIN in the spotlight 💡
Researcher Lidia Cerdán García recently presented our project at the "V Jornadas Científicas PTI+ Salud Global" event in Madrid, Spain.
The event focused on the research conducted at our coordinating institution, the Spanish National Research Council @csic.es!
18.11.2025 07:30 — 👍 0 🔁 0 💬 0 📌 0
In ALADDIN, synthetic biology works hand in hand with #AI!
Using AI, structural predictions can be done to...
💻 Model how nanobodies bind to antigens
💻 Optimise and humanise nanobodies
AI modelling in the project is done by @hebrewuniversity.bsky.social
#ALADDINproject #EICPathfinder
16.11.2025 09:00 — 👍 2 🔁 0 💬 0 📌 0
Microfluidics form a crucial ingredient in our project approach ✅
In ALADDIN, the @inlnano.bsky.social team...
🔬Develops microfluidics devices to select nanobodies from bacteria
🔬Implement the devices into the multidisciplinary ALADDIN platform
#ALADDINproject #EICPathfinder
12.11.2025 08:39 — 👍 1 🔁 0 💬 0 📌 0
Mathematical modelling is a key part of the ALADDIN project 📈
It’s crucial for:
🔎 The identification of therapeutic targets
🔎 The preclinical validation of nanobodies in zebrafish
The power of mathematics is unleashed in our project by InCELLia!
#ALADDINproject #EICPathfinder
10.11.2025 06:30 — 👍 0 🔁 0 💬 0 📌 0
Refining prognosis in pancreatic cancer 🎯
Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma.
A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings.
pubmed.ncbi.nlm.nih....
06.11.2025 10:30 — 👍 0 🔁 0 💬 0 📌 0
Did you know?
By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can...
🔎 Identify novel therapeutic targets
💡 Predict which nanobodies will bind best to their targets
🙌 Validate the efficacy of the nanobodies
aladdin-project.eu/a...
31.10.2025 12:47 — 👍 1 🔁 0 💬 0 📌 0
ALADDIN at the XXI National Meeting of Sociedad Española de Biología Celular 🙌
Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project.
#ALADDINproject #EICPathfinder
31.10.2025 12:23 — 👍 1 🔁 0 💬 0 📌 0
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Nature Reviews Immunology - Fifty years ago, Köhler and Milstein introduced the world to hybridoma technology for the generation of monoclonal antibodies. Scientists have subsequently built...
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
29.10.2025 09:08 — 👍 1 🔁 0 💬 0 📌 0
Stay up to date on the latest ALADDIN news! 📰
Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more:
aladdin-project.eu/n...
23.10.2025 12:00 — 👍 0 🔁 0 💬 0 📌 0
Collaboration fueling innovation 🤝🔬
At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers.
🔗: aladdin-project.eu/c...
16.10.2025 06:15 — 👍 0 🔁 0 💬 0 📌 0
Last month, the ALADDIN team at @inlnano.bsky.social presented the project during an Early-Stage Researcher career fair. 🧬
During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬
14.10.2025 06:30 — 👍 0 🔁 0 💬 0 📌 0
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Nature Reviews Immunology - Fifty years ago, Köhler and Milstein introduced the world to hybridoma technology for the generation of monoclonal antibodies. Scientists have subsequently built...
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
13.10.2025 08:00 — 👍 0 🔁 0 💬 0 📌 0
ALADDIN hosts second annual meeting in Linköping, Sweden – aladdin-project.eu
Recap of our second annual meeting 🔔
Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans.
Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...
12.10.2025 09:35 — 👍 0 🔁 0 💬 0 📌 0
Nanobodies are transforming modern medicine, but the path to discovery is long and costly.
ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡
aladdin-project.eu/a...
09.10.2025 13:00 — 👍 0 🔁 0 💬 0 📌 0
Monoclonal antibodies revolutionized biomedical science and health care
Nature - The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing treatments.
50 years ago, a simple idea changed medicine forever 🧬
Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough.
🔗 Read the story:
07.10.2025 07:30 — 👍 0 🔁 0 💬 0 📌 0
Replicating the human immune system to speed up therapeutic antibody discovery 🔬
ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery.
In the long run, it can contribute to faster, more efficient drug development!
aladdin-project.eu/
30.09.2025 13:00 — 👍 2 🔁 0 💬 0 📌 0
Zebrafish at the forefront of cancer research 🐠
In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance.
In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project.
aladdin-project.eu/l...
26.09.2025 08:15 — 👍 0 🔁 0 💬 0 📌 0
Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction | Nature
There is an urgent need for efficient and innovative therapies to treat brain disorders such as psychiatric and neurodegenerative diseases. Immunotherapies have proved to be efficient in many medical areas, but have not been considered to treat brain diseases due to the poor brain penetration of immunoglobulins1,2. Here we developed a bivalent biparatopic antibody, made of two camelid heavy-chain antibodies (called nanobodies)3, one binding to, and the other potentiating the activity of, homodimeric metabotropic glutamate receptor 2. We show that this bivalent nanobody, given peripherally, reaches the brain and corrects cognitive deficits in two preclinical mouse models with endophenotypes resulting from NMDA receptor hypofunction. Notably, these in vivo effects last for at least 7 days after a single intraperitoneal injection and are maintained after subchronic treatment. Our results establish a proof of concept that nanobodies can target brain receptors, and pave the way for nanobody-based therapeutic strategies for the treatment of brain disorders. A bivalent biparatopic nanobody penetrates the brain, binds to and potentiates the activity of homodimeric metabotropic glutamate receptor 2, correcting cognitive deficits in two preclinical mouse models with endophenotypes resulting from NMDA receptor hypofunction.
Can nanobodies be used to treat brain disorders?
There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com.
Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠
24.09.2025 09:00 — 👍 1 🔁 0 💬 0 📌 0
Nanobodies: tiny but powerful fragments of antibodies first discovered in camelids. 🐪
In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬
aladdin-project.eu/
18.09.2025 06:00 — 👍 0 🔁 0 💬 0 📌 0
ALADDIN hosts second annual meeting in Linköping, Sweden – aladdin-project.eu
Second annual meeting: completed 🚀
Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks.
Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...
16.09.2025 07:38 — 👍 2 🔁 1 💬 0 📌 0
Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery
Signal Transduction and Targeted Therapy - Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery
Nanobodies targeting lung cancer 🫁
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.
10.09.2025 12:00 — 👍 1 🔁 0 💬 0 📌 0
The second annual ALADDIN project meeting has come to an end! 👏
We thank our hosts from @liu.se for a well-organised meeting and our project partners for their presentations & insightful conversations.
As we approach our halfway milestone, things will only speed up!
#EICPathfinder
04.09.2025 12:37 — 👍 3 🔁 1 💬 0 📌 0
Day 1 of our meeting is drawing to a close 🔎
We've discussed...
🔸 Biological & AI technologies for nanobody (Nb) discovery & optimisation
🔸 Developing a microfluidic cell sorting device to discover Nbs
🔸 Technologies to assess Nb candidates
🔸 Identifying targets in pancreatic & colorectal cancers
03.09.2025 14:51 — 👍 0 🔁 0 💬 0 📌 0
Our second annual meeting has begun! 📢
Our consortium has gathered at @liu.se to discuss project progress & future tasks. 🧬
Our project coordinator, Luis Ángel Fernández from @cnb-csic.bsky.social, welcomed all partners & explained the agenda of the upcoming two days.
#EICPathfinder
03.09.2025 07:13 — 👍 3 🔁 0 💬 0 📌 0
One day left for our annual project meeting!
The ALADDIN project partners are arriving in Linköping, Sweden 🇸🇪, tomorrow to kick off our second in-person meeting.
Keep an eye on our social media accounts for updates! 🙌
@liu.se, thank you for having us! #EICPathfinder
02.09.2025 09:30 — 👍 1 🔁 0 💬 0 📌 0
In our blog, Lasse Jensen, Senior Associate Professor at @liu.se & founder of BioReperia, explains:
💡 His team’s role in ALADDIN
🐠 Why zebrafish are used to test nanobody efficacy
💎 How the developed zebrafish models can be used beyond the project
aladdin-project.eu/l...
28.08.2025 14:00 — 👍 2 🔁 0 💬 0 📌 0
A joint cancer research community at Linköping University and Region Östergötland, Sweden. 🇸🇪
https://liu.se/en/research/cancer
#LinköpingComprehensiveCancerCenter
#SwedishCancerResearch
Nature Communications is an open access journal publishing high-quality research in all areas of the biological, physical, chemical, clinical, social, and Earth sciences.
www.nature.com/ncomms/
Computational Structural Biology, The Hebrew University of Jerusalem
Turning complex information into insightful communications. Helsinki-born, Madrid-based. Strategic communications at the Marie Curie Alumni Association (MCAA) and Zirka InnoTech ✨
Organismo Público de Investigación que promueve, financia y gestiona investigación biomédica y sanitaria en España. Ciencia para mejorar la salud pública.
Canal de divulgación médica con rigor científico de Quirónsalud, grupo de salud líder en España.
News and information from the European Commission. Social media and data protection policy: http://europa.eu/!MnfFmT
Israel's leading academic and research institution, serving 25,000 students from 90 countries.
Innovation is our only tradition.
www.liu.se/en
CSIC Cultura Científica. En el CSIC nos gusta hacer ciencia y también compartirla. Te contamos nuestras iniciativas para acercar la ciencia a todos los públicos.
Novedades desde el Centro Nacional de Biotecnología del CSIC (Madrid, España)
official Bluesky account (check username👆)
Bugs, feature requests, feedback: support@bsky.app
